In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: IGI

This article was originally published in The Rose Sheet

Executive Summary

IGI: Secondary stock offering of 110,000 common shares expected to net up to $570,625 for the selling shareholders, according to a May 15 preliminary prospectus. IGI President John Gallo and Allergan, Inc. will sell 85,000 ($440,938) and 25,000 shares ($129,688), respectively. Gallo will still own 578,397 shares after divesting his stock and Allergan will no longer hold a stake in IGI. Allergan received its 25,000 shares valued at $175,000 Jan. 9 under a "mutual release of claims" settlement between the two companies regarding breach of duty...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts